

# Supplemental Information

## **Allelic strengths of encephalopathy-associated *UBA5* variants correlate between *in vivo* and *in vitro* assays**

Xueyang Pan<sup>1,2</sup>, Albert N. Alvarez<sup>3</sup>, Mengqi Ma<sup>1,2</sup>, Shenzhao Lu<sup>1,2</sup>, Michael W. Crawford<sup>3</sup>, Lauren C. Briere<sup>4</sup>, Oguz Kanca<sup>1,2</sup>, Shinya Yamamoto<sup>1,2,5</sup>, David A. Sweetser<sup>4,6</sup>, Jenny L. Wilson<sup>7</sup>, Ruth J. Napier<sup>3,8,9</sup>, Jonathan N. Pruneda<sup>3,#</sup>, Hugo J. Bellen<sup>1,2,5,#</sup>

1 Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA

2 Jan & Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX 77030, USA

3 Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR 97239, USA

4 Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA

5 Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA

6 Division of Medical Genetics & Metabolism, Massachusetts General Hospital for Children, Boston, MA 02114, USA

7 Division of Pediatric Neurology, Department of Pediatrics, Oregon Health & Science University, Portland, OR 97239, USA

8 VA Portland Health Care System, Portland, OR 97239, USA


9 Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR 97239, USA

# Correspondence: hbellan@bcm.edu, pruneda@ohsu.edu

## 1 Case report

2 The reported proband is a boy with axial hypotonia, generalized dystonia, lower extremity spasticity,  
3 global developmental delay, esotropia and failure to thrive. An electroencephalogram (EEG) showed  
4 multifocal epileptiform discharges in drowsiness and sleep. However, he has not had seizures. Two  
5 magnetic resonance imaging (MRI) studies at different ages were read as normal, although on review  
6 show a slightly thin corpus callosum, posterior periventricular white matter T2 hyperintensity resulting  
7 in increased conspicuity of the subcortical U-fibers and widening of the Sylvian fissures (Figure S1). He  
8 is not microcephalic. For more information about the clinical record of the proband please contact the  
9 corresponding author.

10 On trio exome sequencing, the proband was found to have compound heterozygous variants in *UBA5*,  
11 NM\_024818.6:c.169A>G (p.Met57Val) and c.935A>T (p.Gln312Leu). The two variants are in *trans*  
12 phase. The p.Met57Val variant has been reported in one individual with DEE44 (Colin *et al*, 2016). The  
13 p.Gln312Leu variant has not been previously reported. Neither variant is reported in the gnomAD  
14 database v.2.1.1 (<https://gnomad.broadinstitute.org>). Both variants are predicted to be damaging or  
15 probably damaging by multiple pathogenicity prediction tools (Table S3).



**Figure S1. Brain magnetic resonance imaging (MRI) images**

(A) Axial T2 image showing periventricular T2 hyperintensity (blue arrow) resulting in prominence of the subcortical U-fibers (white arrows).

(B) Sagittal flair showing mild thinning of the corpus callosum (red arrow).

(C) Axial flair image demonstrating widening of the sylvian fissures (white asterisks).

**Table S1. Summary of genotypes of the reported cases**

| References                                                             | Family | Allele #1                      | Allele #2                    |
|------------------------------------------------------------------------|--------|--------------------------------|------------------------------|
| Colin, <i>et al.</i> , 2016 (Colin <i>et al.</i> , 2016)               | A      | p.Ala371Thr (IA <sup>†</sup> ) | p.Gln302*                    |
|                                                                        | B      | p.Ala371Thr (IA)               | p.Lys324Asnfs*14             |
|                                                                        | C      | p.Asp389Tyr (IA)               | p.Val260Met (II)             |
|                                                                        | D      | p.Met57Val (II)                | p.Gly168Glu (III)            |
| Muona, <i>et al.</i> , 2016 (Muona <i>et al.</i> , 2016)               | A      | p.Ala371Thr (IA)               | p.Arg55His (III)             |
|                                                                        | B      | p.Ala371Thr (IA)               | p.Tyr285*                    |
|                                                                        | C, E   | p.Ala371Thr (IA)               | p.Arg188*                    |
|                                                                        | D      | p.Ala371Thr (IA)               | p.Arg61*                     |
| Arnadottir, <i>et al.</i> , 2017 (Arnadottir <i>et al.</i> , 2017)     |        | p.Ala371Thr (IA)               | p.Ala288= (splicing variant) |
| Daida, <i>et al.</i> , 2018 (Daida <i>et al.</i> , 2018)               |        | p.Tyr72Cys (IB)                | Deletion                     |
| Mignon-Ravix, <i>et al.</i> , 2018 (Mignon-Ravix <i>et al.</i> , 2018) |        | p.Tyr53Phe (II) <sup>††</sup>  | p.Tyr53Phe (II)              |
| Low, <i>et al.</i> , 2019 (Low <i>et al.</i> , 2019)                   |        | p.Asp389Gly (IA)               | Deletion                     |
| Briere, <i>et al.</i> , 2021 (Briere <i>et al.</i> , 2021)             | A      | p.Ala371Thr (IA)               | p.Cys303Arg (III)            |
|                                                                        | B      | p.Ala371Thr (IA)               | p.Arg188*                    |
|                                                                        | C      | p.Ala371Thr (IA)               | p.Leu254Pro (III)            |
|                                                                        | D      | p.Ala371Thr (IA)               | p.Cys303Arg (III)            |
| This study                                                             |        | p.Met57Val (II)                | p.Gln312Leu (IB)             |

<sup>†</sup> The variant classification using fly phenotypic assays (results shown in Figure 3)

1 †† Consanguineous family

2

3 **Table S2. Clinical features of individuals with *UBA5*-associated DEE44**

4 (See separate Excel table)

5

6 **Table S3. Bioinformatic predictions of the pathogenicity of reported *UBA5* variants**

|                            | Variant 1                 | Variant 2                 |
|----------------------------|---------------------------|---------------------------|
| Genomic position (GRCh38)  | 3:132665830A>G            | 3:132394214A>T            |
| Amino acid change          | p.Met57Val                | p.Gln312Leu               |
| Allele frequency in gnomAD | Absent                    | Absent                    |
| CADD score                 | 25.3                      | 29.1                      |
| SIFT                       | Damaging                  | Damaging                  |
| PolyPhen2                  | 1.000 (probably damaging) | 0.999 (probably damaging) |
| MutationTaster             | Disease causing           | Disease causing           |
| PROVEAN                    | -3.18 (deleterious)       | -6.59 (deleterious)       |

7

## 1   **References**

- 2    Arnadottir GA, Jensson BO, Marelsson SE, Sulem G, Oddsson A, Kristjansson RP, Benonisdottir S,  
3    Gudjonsson SA, Masson G, Thorisson GA *et al* (2017) Compound heterozygous mutations in UBA5  
4    causing early-onset epileptic encephalopathy in two sisters. *BMC Med Genet* 18: 103
- 5    Briere LC, Walker MA, High FA, Cooper C, Rogers CA, Callahan CJ, Ishimura R, Ichimura Y, Caruso  
6    PA, Sharma N *et al* (2021) A description of novel variants and review of phenotypic spectrum in  
7    UBA5-related early epileptic encephalopathy. *Cold Spring Harb Mol Case Stud* 7
- 8    Colin E, Daniel J, Ziegler A, Wakim J, Scrivo A, Haack TB, Khiati S, Denomme AS, Amati-Bonneau  
9    P, Charif M *et al* (2016) Biallelic Variants in UBA5 Reveal that Disruption of the UFM1 Cascade Can  
10   Result in Early-Onset Encephalopathy. *Am J Hum Genet* 99: 695-703
- 11   Daida A, Hamano SI, Ikemoto S, Matsuura R, Nakashima M, Matsumoto N, Kato M (2018) Biallelic  
12   loss-of-function UBA5 mutations in a patient with intractable West syndrome and profound failure to  
13   thrive. *Epileptic Disord* 20: 313-318
- 14   Low KJ, Baptista J, Babiker M, Caswell R, King C, Ellard S, Scurr I (2019) Hemizygous UBA5  
15   missense mutation unmasks recessive disorder in a patient with infantile-onset encephalopathy,  
16   acquired microcephaly, small cerebellum, movement disorder and severe neurodevelopmental delay.  
17   *Eur J Med Genet* 62: 97-102
- 18   Mignon-Ravix C, Milh M, Kaiser CS, Daniel J, Riccardi F, Cacciagli P, Nagara M, Busa T, Liebau E,  
19   Villard L (2018) Abnormal function of the UBA5 protein in a case of early developmental and epileptic  
20   encephalopathy with suppression-burst. *Hum Mutat* 39: 934-938
- 21   Muona M, Ishimura R, Laari A, Ichimura Y, Linnankivi T, Keski-Filppula R, Herva R, Rantala H,  
22   Paetau A, Poyhonen M *et al* (2016) Biallelic Variants in UBA5 Link Dysfunctional UFM1 Ubiquitin-like  
23   Modifier Pathway to Severe Infantile-Onset Encephalopathy. *Am J Hum Genet* 99: 683-694

24